Autoinflammatory disorders, pain, and neural regulation of inflammation

Dermatologic Clinics

Volumn 31, Issue 3, 2013, Pages 461-470

  Chen, Michael C ^a   Meckfessel, Matthew H ^a  

^a Galderma Laboratories LP   (United States)

Author keywords

Autoinflammatory disorders; IL 1 ; Inflammasome; Neural crosstalk; Neuromodulation; Pain

Indexed keywords

ALENDRONIC ACID; AMITRIPTYLINE; BIOLOGICAL PRODUCT; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; CRYOPYRIN; DIMETHYL SULFOXIDE; DULOXETINE; GABAPENTIN; HYDROXYZINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MEMBRANE PROTEIN; OXYCODONE; PENTOSAN POLYSULFATE; PREGABALIN; PROTEIN AIM2; PROTEIN NLRC4; PROTEIN NLRP1; THIOCTIC ACID; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ACNE; ADAPTIVE IMMUNITY; ANTIBODY TITER; AUTOINFLAMMATORY DISEASE; BINDING AFFINITY; BLAU SYNDROME; CELL DIFFERENTIATION; CINCA SYNDROME; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; FAMILIAL MEDITERRANEAN FEVER; GOUT; HEREDITARY PERIODIC FEVER; HUMAN; IMMUNOREACTIVITY; INFLAMMATION; INFLAMMATORY PAIN; INNATE IMMUNITY; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTERLEUKIN 1 RECEPTOR AGONIST DEFICIENCY; INTERSTITIAL CYSTITIS; MEVALONATE KINASE DEFICIENCY; MOLECULAR CLONING; MOLECULAR INTERACTION; NEUROMODULATION; NEUROPATHIC PAIN; NEUROTRANSMISSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PAPA SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; ROSACEA; T LYMPHOCYTE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

AUTOINFLAMMATORY DISORDERS; IL-1Β; INFLAMMASOME; NEURAL CROSSTALK; NEUROMODULATION; PAIN;

AUTOIMMUNE DISEASES; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; INFLAMMATION; INTERLEUKIN-1BETA; PAIN;

EID: 84879886647     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2013.04.002     Document Type: Review

References (92)

1. Kastner D.L., Aksentijevich I., Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell 2010, 140(6):784-790.
2. Brydges S., Kastner D.L. The systemic autoinflammatory diseases: inborn errors of the innate immune system. Curr Top Microbiol Immunol 2006, 305:127-160.
3. Kambe N., Satoh T., Tanizaki H., et al. Enhanced NF-kappaB activation with an inflammasome activator correlates with activity of autoinflammatory disease associated with NLRP3 mutations outside of exon 3: comment on the article by Jeru etal. Arthritis Rheum 2010, 62(10):3123-3124. [author reply: 3124-5].
4. Menu P., Vince J.E. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin Exp Immunol 2011, 166(1):1-15.
5. Smith E.J., Allantaz F., Bennett L., et al. Clinical, molecular, and genetic characteristics of PAPA syndrome: a review. Curr Genomics 2010, 11(7):519-527.
6. Pastores G.M., Michels V.V., Stickler G.B., et al. Autosomal dominant granulomatous arthritis, uveitis, skin rash, and synovial cysts. JPediatr 1990, 117(3):403-408.
7. Basbaum A.I., Bautista D.M., Scherrer G., et al. Cellular and molecular mechanisms of pain. Cell 2009, 139(2):267-284.
8. Kavoussi B., Ross B.E. The neuroimmune basis of anti-inflammatory acupuncture. Integr Cancer Ther 2007, 6(3):251-257.
9. Gross O., Thomas C.J., Guarda G., et al. The inflammasome: an integrated view. Immunol Rev 2011, 243(1):136-151.
10. Franchi L., Eigenbrod T., Munoz-Planillo R., et al. Theinflammasome: a caspase-1-activation platform that regulates immune responses and diseasepathogenesis. Nat Immunol 2009, 10(3):241-247.
11. Ozkurede V.U., Franchi L. Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes. Clin Exp Immunol 2012, 167(3):382-390.
12. Bauernfeind F.G., Horvath G., Stutz A., et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. JImmunol 2009, 183(2):787-791.
13. Franchi L., Munoz-Planillo R., Reimer T., et al. Inflammasomes as microbial sensors. Eur J Immunol 2010, 40(3):611-615.
14. Joly S., Sutterwala F.S. Fungal pathogen recognition by the NLRP3 inflammasome. Virulence 2010, 1(4):276-280.
15. Rathinam V.A., Fitzgerald K.A. Inflammasomes and anti-viral immunity. JClin Immunol 2010, 30(5):632-637.
16. Ferrari D., Pizzirani C., Adinolfi E., et al. The P2X7 receptor: a key player in IL-1 processing and release. JImmunol 2006, 176(7):3877-3883.
17. Martinon F., Petrilli V., Mayor A., et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440(7081):237-241.
18. Duewell P., Kono H., Rayner K.J., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464(7293):1357-1361.
19. Masters S.L., Dunne A., Subramanian S.L., et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 2010, 11(10):897-904.
20. Sohar E., Gafni J., Pras M., et al. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967, 43(2):227-253.
21. Feng J., Zhang Z., Li W., et al. Missense mutationsinthe MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. PLoS One 2009, 4(12):e8480.
22. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell 1997, 90(4):797-807.
23. Yildirim K., Uzkeser H., Keles M., et al. Relationship between serum interleukin-1beta levels and acute phase response proteins in patients with familial Mediterranean fever. Biochem Med (Zagreb) 2012, 22(1):109-113.
24. Nesterovitch A.B., Hoffman M.D., Simon M., et al. Mutations in the PSTPIP1 gene and aberrant splicing variants in patients with pyoderma gangrenosum. Clin Exp Dermatol 2011, 36(8):889-895.
25. Contassot E., Beer H.D., French L.E. Interleukin-1, inflammasomes, autoinflammation and the skin. Swiss Med Wkly 2012, 142:w13590.
26. Shoham N.G., Centola M., Mansfield E., et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci US A 2003, 100(23):13501-13506.
27. Prieur A.M. Arecently recognised chronic inflammatory disease of early onset characterised by the triad of rash, central nervous system involvement and arthropathy. Clin Exp Rheumatol 2001, 19(1):103-106.
28. Hoffman H.M., Mueller J.L., Broide D.H., et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001, 29(3):301-305.
29. Feldmann J., Prieur A.M., Quartier P., et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 2002, 71(1):198-203.
30. Agostini L., Martinon F., Burns K., et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004, 20(3):319-325.
31. Hoffman H.M., Throne M.L., Amar N.J., et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008, 58(8):2443-2452.
32. Lachmann H.J., Kone-Paut I., Kuemmerle-Deschner J.B., et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. NEngl J Med 2009, 360(23):2416-2425.
33. Brydges S.D., Mueller J.L., McGeough M.D., et al. Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity 2009, 30(6):875-887.
34. Meng G., Zhang F., Fuss I., et al. Amutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity 2009, 30(6):860-874.
35. Dalbeth N., Haskard D.O. Mechanisms of inflammation in gout. Rheumatology (Oxford) 2005, 44(9):1090-1096.
36. Dinarello C.A. Blocking interleukin-1beta in acute and chronic autoinflammatory diseases. JIntern Med 2011, 269(1):16-28.
37. Joosten L.A., Netea M.G., Mylona E., et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1beta production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum 2010, 62(11):3237-3248.
38. Kingsbury S.R., Conaghan P.G., McDermott M.F. The role of the NLRP3 inflammasome in gout. JInflamm Res 2011, 4:39-49.
39. Simon A., Cuisset L., Vincent M.F., et al. Molecular analysis of the mevalonate kinase gene in a cohort of patients with the hyper-igd and periodic fever syndrome: its application as a diagnostic tool. Ann Intern Med 2001, 135(5):338-343.
40. Goldfinger S. The inherited autoinflammatory syndrome: a decade of discovery. Trans Am Clin Climatol Assoc 2009, 120:413-418.
41. Pontillo A., Paoluzzi E., Crovella S. The inhibition of mevalonate pathway induces upregulation of NALP3 expression: new insight in the pathogenesis of mevalonate kinase deficiency. Eur J Hum Genet 2010, 18(7):844-847.
42. Maedler K., Sergeev P., Ris F., et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. JClin Invest 2002, 110(6):851-860.
43. Boni-Schnetzler M., Thorne J., Parnaud G., et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. JClin Endocrinol Metab 2008, 93(10):4065-4074.
44. Boni-Schnetzler M., Boller S., Debray S., et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 2009, 150(12):5218-5229.
45. Maedler K., Sergeev P., Ehses J.A., et al. Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci U S A 2004, 101(21):8138-8143.
46. Stienstra R., Joosten L.A., Koenen T., et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab 2010, 12(6):593-605.
47. McDermott M.F., Aksentijevich I., Galon J., et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999, 97(1):133-144.
48. Turner M.D., Chaudhry A., Nedjai B. Tumour necrosis factor receptor trafficking dysfunction opens the TRAPS door to pro-inflammatory cytokine secretion. Biosci Rep 2012, 32(2):105-112.
49. Tromp G., Kuivaniemi H., Raphael S., et al. Genetic linkage of familial granulomatous inflammatory arthritis, skin rash, and uveitis to chromosome 16. Am J Hum Genet 1996, 59(5):1097-1107.
50. Miceli-Richard C., Lesage S., Rybojad M., et al. CARD15 mutations in Blau syndrome. Nat Genet 2001, 29(1):19-20.
51. van Duist M.M., Albrecht M., Podswiadek M., et al. Anew CARD15 mutation in Blau syndrome. Eur J Hum Genet 2005, 13(6):742-747.
52. Girardin S.E., Boneca I.G., Viala J., et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. JBiol Chem 2003, 278(11):8869-8872.
53. Inohara N., Ogura Y., Fontalba A., et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. JBiol Chem 2003, 278(8):5509-5512.
54. Aksentijevich I., Masters S.L., Ferguson P.J., et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. NEngl J Med 2009, 360(23):2426-2437.
55. Reddy S., Jia S., Geoffrey R., et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. NEngl J Med 2009, 360(23):2438-2444.
56. Jesus A.A., Osman M., Silva C.A., et al. Anovel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: description of two unrelated cases from Brazil. Arthritis Rheum 2011, 63(12):4007-4017.
57. Scholz J., Woolf C.J. Can we conquer pain?. Nat Neurosci 2002, 5(Suppl):1062-1067.
58. Janig W., Grossmann L., Gorodetskaya N. Mechano- and thermosensitivity of regenerating cutaneous afferent nerve fibers. Exp Brain Res 2009, 196(1):101-114.
59. Wu G., Ringkamp M., Hartke T.V., et al. Early onset of spontaneous activity in uninjured C-fiber nociceptors after injury to neighboring nerve fibers. JNeurosci 2001, 21(8):RC140.
60. Binshtok A.M., Wang H., Zimmermann K., et al. Nociceptors are interleukin-1beta sensors. JNeurosci 2008, 28(52):14062-14073.
61. Watkins L.R., Maier S.F. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol Rev 2002, 82(4):981-1011.
62. Milligan E.D., Twining C., Chacur M., et al. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. JNeurosci 2003, 23(3):1026-1040.
63. Hucho T., Levine J.D. Signaling pathways in sensitization: toward a nociceptor cell biology. Neuron 2007, 55(3):365-376.
64. Ren K., Torres R. Role of interleukin-1beta during pain and inflammation. Brain Res Rev 2009, 60(1):57-64.
65. Cunha T.M., Verri W.A. Neutrophils: are they hyperalgesic or anti-hyperalgesic?. JLeukoc Biol 2006, 80(4):727-728. [author reply: 729-30].
66. Kiguchi N., Kobayashi Y., Kishioka S. Chemokines and cytokines in neuroinflammation leading to neuropathic pain. Curr Opin Pharmacol 2012, 12(1):55-61.
67. So A., De Smedt T., Revaz S., et al. Apilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9(2):R28.
68. McGonagle D., Tan A.L., Shankaranarayana S., et al. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 2007, 66(12):1683-1684.
69. So A., De Meulemeester M., Pikhlak A., et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010, 62(10):3064-3076.
70. Boulton A.J., Malik R.A., Arezzo J.C., et al. Diabetic somatic neuropathies. Diabetes Care 2004, 27(6):1458-1486.
71. Tesfaye S., Boulton A.J., Dyck P.J., et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010, 33(10):2285-2293.
72. Larsen C.M., Faulenbach M., Vaag A., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. NEngl J Med 2007, 356(15):1517-1526.
73. Larsen C.M., Faulenbach M., Vaag A., et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009, 32(9):1663-1668.
74. Chen T.C., Wu J.J., Chang W.P., et al. Spontaneous inflammatory pain model from a mouse line with N-ethyl-N-nitrosourea mutagenesis. JBiomed Sci 2012, 19:55.
75. Marshall K. Interstitial cystitis: understanding the syndrome. Altern Med Rev 2003, 8(4):426-437.
76. Lau T.C., Bengtson J.M. Management strategies for painful bladder syndrome. Rev Obstet Gynecol 2010, 3(2):42-48.
77. Moutzouris D.A., Falagas M.E. Interstitial cystitis: an unsolved enigma. Clin J Am Soc Nephrol 2009, 4(11):1844-1857.
78. Sant G.R., Kempuraj D., Marchand J.E., et al. The mast cell in interstitial cystitis: role in pathophysiology andpathogenesis. Urology 2007, 69(Suppl 4):34-40.
79. Erickson D.R., Xie S.X., Bhavanandan V.P., et al. Acomparison of multiple urine markers for interstitial cystitis. JUrol 2002, 167(6):2461-2469.
80. Liu H.T., Kuo H.C. Increased urine and serum nerve growth factor levels in interstitial cystitis suggest chronic inflammation is involved in the pathogenesis of disease. PLoS One 2012, 7(9):e44687.
81. Erickson D.R., Tomaszewski J.E., Kunselman A.R., et al. Urine markers do not predict biopsy findings or presence of bladder ulcers in interstitial cystitis/painful bladder syndrome. JUrol 2008, 179(5):1850-1856.
82. van de Merwe J.P. Interstitial cystitis and systemic autoimmune diseases. Nat Clin Pract Urol 2007, 4(9):484-491.
83. Grover S., Srivastava A., Lee R., et al. Role of inflammation in bladder function and interstitial cystitis. Ther Adv Urol 2011, 3(1):19-33.
84. Kummer J.A., Broekhuizen R., Everett H., et al. Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response. JHistochem Cytochem 2007, 55(5):443-452.
85. Nakamura Y., Kambe N., Saito M., et al. Mast cells mediate neutrophil recruitment and vascular leakage through the NLRP3 inflammasome in histamine-independent urticaria. JExp Med 2009, 206(5):1037-1046.
86. Gerber P.A., Buhren B.A., Steinhoff M., et al. Rosacea: the cytokine and chemokine network. JInvestig Dermatol Symp Proc 2011, 15(1):40-47.
87. Yamasaki K., Gallo R.L. The molecular pathology of rosacea. JDermatol Sci 2009, 55(2):77-81.
88. Brink N., Szamel M., Young A.R., et al. Comparative quantification of IL-1beta, IL-10, IL-10r, TNFalpha and IL-7 mRNA levels in UV-irradiated human skin invivo. Inflamm Res 2000, 49(6):290-296.
89. Faustin B., Reed J.C. Sunburned skin activates inflammasomes. Trends Cell Biol 2008, 18(1):4-8.
90. Schwab V.D., Sulk M., Seeliger S., et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. JInvestig Dermatol Symp Proc 2011, 15(1):53-62.
91. Aubdool A.A., Brain S.D. Neurovascular aspects of skin neurogenic inflammation. JInvestig Dermatol Symp Proc 2011, 15(1):33-39.
92. Peters K.M. Neuromodulation for the treatment of refractory interstitial cystitis. Rev Urol 2002, 4(Suppl 1):S36-S43.